PBC Partner, Chris Coffin, Appointed to Zoloft Birth Defect Litigation Leadership Committtee
July 16th, 2012
Judge Cynthia Rufe, a federal court judge in the Eastern District of Pennsylvania, has appointed Chris Coffin as one of the members of the Plaintiffs’ Steering Committee in the national Zoloft Birth Defect Litigation. Chris will join several other lawyers from around the country in leading the Zoloft birth defect litigation on behalf of hundreds of plaintiffs injured by the Pfizer drug, Zoloft.
Chris Coffin has years of experience and background in litigating complex cases involving defective pharmaceuticals and medical devices, environmental contamination, product liability, toxic torts and consumer fraud claims. He has been heavily involved in multiple class action and mass tort cases throughout the United States and has served as a leader in many national lawsuits representing thousands of individuals.
As the leader of Pendley, Baudin & Coffin’s pharmaceutical and medical device litigation practice, Chris Coffin has prosecuted cases against pharmaceutical and medical device manufacturers for over nine years and has been licensed as a registered nurse for approximately fifteen years. The combination of his background in nursing and law provides him with a unique perspective when litigating pharmaceutical and medical device cases. The knowledge and experience that he possesses in the area of pharmaceutical and medical device litigation has helped the firm to successfully litigate thousands of cases addressing drug and device manufacturing defects, design defects, inadequate warnings and fraudulent misrepresentations made by manufacturers. The firm has litigated cases against some of the largest pharmaceutical and medical device companies in the world and has led national pharmaceutical cases involving clients from almost every state in the country. For more information about Chris see his biography under the Attorneys section. To read more about birth defects linked to anti-depressants click here.
This entry was posted in firm-news. Bookmark the permalink.Comments are closed.